AR121898A1 - Compuestos y métodos dirigidos a interleucina-34 - Google Patents
Compuestos y métodos dirigidos a interleucina-34Info
- Publication number
- AR121898A1 AR121898A1 ARP210101065A ARP210101065A AR121898A1 AR 121898 A1 AR121898 A1 AR 121898A1 AR P210101065 A ARP210101065 A AR P210101065A AR P210101065 A ARP210101065 A AR P210101065A AR 121898 A1 AR121898 A1 AR 121898A1
- Authority
- AR
- Argentina
- Prior art keywords
- comprises seq
- lcdr2
- hcdr2
- lcdr3
- hcdr3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a anticuerpos IL-34, composiciones que los comprenden y métodos para usar los anticuerpos y/o composiciones de estos para tratar enfermedades mediadas por el sistema inmunitario tales como enfermedades neurodegenerativas, por ejemplo, la enfermedad de Alzheimer o una enfermedad de tauopatía. Reivindicación 1: Un anticuerpo que se une a IL-34 humana, en donde el anticuerpo comprende una región variable de cadena pesada (VH) y una región variable de cadena ligera (VL), en donde la VH comprende regiones determinantes de complementariedad de la cadena pesada (HCDR) HCDR1, HCDR2 y HCDR3, y la VL comprende regiones determinantes de complementariedad de la cadena ligera (LCDR) LCDR1, LCDR2 y LCDR3, en donde la HCDR1 comprende la SEQ ID Nº 5, la HCDR2 comprende la SEQ ID Nº 6, la HCDR3 comprende la SEQ ID Nº 7, la LCDR1 comprende la SEQ ID Nº 8, la LCDR2 comprende la SEQ ID Nº 9 y la LCDR3 comprende la SEQ ID Nº 10. Reivindicación 7: Un anticuerpo que se une a IL-34 murina, en donde el anticuerpo comprende una VH y una VL, en donde la VH comprende HCDR1, HCDR2 y HCDR3, y la VL comprende LCDR1, LCDR2 y LCDR3, en donde la HCDR1 comprende la SEQ ID Nº 23, la HCDR2 comprende la SEQ ID Nº 24, la HCDR3 comprende la SEQ ID Nº 25, la LCDR1 comprende la SEQ ID Nº 26, la LCDR2 comprende la SEQ ID Nº 27 y la LCDR3 comprende la SEQ ID Nº 28.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017748P | 2020-04-30 | 2020-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121898A1 true AR121898A1 (es) | 2022-07-20 |
Family
ID=75905053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101065A AR121898A1 (es) | 2020-04-30 | 2021-04-21 | Compuestos y métodos dirigidos a interleucina-34 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11649280B2 (es) |
| EP (1) | EP4142880A1 (es) |
| JP (1) | JP2023524515A (es) |
| KR (1) | KR20230003187A (es) |
| CN (1) | CN115867576A (es) |
| AR (1) | AR121898A1 (es) |
| AU (1) | AU2021264421A1 (es) |
| BR (1) | BR112022021743A2 (es) |
| CA (1) | CA3176669A1 (es) |
| CO (1) | CO2022015893A2 (es) |
| CR (1) | CR20220557A (es) |
| EC (1) | ECSP22084245A (es) |
| IL (1) | IL297638A (es) |
| MX (1) | MX2022013617A (es) |
| PE (1) | PE20231030A1 (es) |
| TW (1) | TWI799840B (es) |
| WO (1) | WO2021222025A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023076971A1 (en) * | 2021-10-29 | 2023-05-04 | Eli Lilly Company | Compounds and methods targeting interleukin-34 |
| AU2022379194A1 (en) * | 2021-10-29 | 2024-05-02 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| MA40406A (fr) | 2014-07-28 | 2016-02-04 | Nogra Pharma Ltd | Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin |
| EP3233897B1 (en) | 2014-12-19 | 2021-02-17 | Universite de Nantes | Anti il-34 antibodies |
| JP2018516933A (ja) * | 2015-06-02 | 2018-06-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法 |
| JP7356994B2 (ja) | 2018-03-02 | 2023-10-05 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 網膜炎症および神経変性を処置するためのｉｌ－３４の使用 |
-
2021
- 2021-04-21 AR ARP210101065A patent/AR121898A1/es unknown
- 2021-04-21 TW TW110114408A patent/TWI799840B/zh active
- 2021-04-23 BR BR112022021743A patent/BR112022021743A2/pt unknown
- 2021-04-23 PE PE2022002506A patent/PE20231030A1/es unknown
- 2021-04-23 IL IL297638A patent/IL297638A/en unknown
- 2021-04-23 AU AU2021264421A patent/AU2021264421A1/en active Pending
- 2021-04-23 MX MX2022013617A patent/MX2022013617A/es unknown
- 2021-04-23 CA CA3176669A patent/CA3176669A1/en active Pending
- 2021-04-23 CN CN202180047218.0A patent/CN115867576A/zh active Pending
- 2021-04-23 KR KR1020227041857A patent/KR20230003187A/ko active Search and Examination
- 2021-04-23 EP EP21725335.0A patent/EP4142880A1/en active Pending
- 2021-04-23 US US17/238,549 patent/US11649280B2/en active Active
- 2021-04-23 WO PCT/US2021/028861 patent/WO2021222025A1/en active Application Filing
- 2021-04-23 JP JP2022566385A patent/JP2023524515A/ja active Pending
- 2021-04-23 CR CR20220557A patent/CR20220557A/es unknown
-
2022
- 2022-10-28 EC ECSENADI202284245A patent/ECSP22084245A/es unknown
- 2022-11-03 CO CONC2022/0015893A patent/CO2022015893A2/es unknown
-
2023
- 2023-04-07 US US18/297,072 patent/US20230279098A1/en active Pending
- 2023-04-07 US US18/297,099 patent/US20240141033A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023524515A (ja) | 2023-06-12 |
| ECSP22084245A (es) | 2022-11-30 |
| EP4142880A1 (en) | 2023-03-08 |
| TW202206458A (zh) | 2022-02-16 |
| US20240141033A1 (en) | 2024-05-02 |
| MX2022013617A (es) | 2022-11-16 |
| KR20230003187A (ko) | 2023-01-05 |
| CR20220557A (es) | 2022-11-28 |
| CO2022015893A2 (es) | 2022-11-18 |
| US20210363232A1 (en) | 2021-11-25 |
| TWI799840B (zh) | 2023-04-21 |
| US11649280B2 (en) | 2023-05-16 |
| BR112022021743A2 (pt) | 2022-12-06 |
| AU2021264421A1 (en) | 2022-11-24 |
| US20230279098A1 (en) | 2023-09-07 |
| WO2021222025A1 (en) | 2021-11-04 |
| IL297638A (en) | 2022-12-01 |
| PE20231030A1 (es) | 2023-07-10 |
| CA3176669A1 (en) | 2021-11-04 |
| CN115867576A (zh) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231049A1 (es) | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| IL276695A (en) | Antibodies, pharmaceuticals and their uses | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
| AR121898A1 (es) | Compuestos y métodos dirigidos a interleucina-34 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| JP2016135783A5 (es) | ||
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| JP2016538876A5 (es) | ||
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| CA2863714A1 (en) | Cdim binding proteins and uses thereof | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| PE20180041A1 (es) | Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| CO2018001256A2 (es) | Anticuerpos anti-cd154 y métodos para producir los mismos | |
| RU2017145094A (ru) | Нейтрализующие связывающие молекулы, направленные против вируса гриппа, и пути их применения |